-
-
An experimental blood oxygenation device has the potential to help thousands of patients with severe emphysema or other lung conditions. The device has been thoroughly tested in laboratory animals, but human trials would involve major invasive procedures for research participants and place them at very high risk of death or serious complications.
-
Paramedics in the Denver area will be administering an experimental blood substitute to patients who meet certain criteria under an unusual research protocol that allows patients to be recruited without giving informed consent.
-
In recent years, efforts to address substance abuse among pregnant women have moved from being barely visible public health initiatives to controversial political battlegrounds.
-
-
In July 2003, the Office of Population Affairs (OPA) at the U.S. Department of Health and Human Services formally requested applications for $49 million for family planning service delivery under the Title X program for FY 2004. The announcement contains a number of new program priorities that will affect the delivery of subsidized family planning services for millions of low-income women and teens in the years to come.
-
You have just examined a young woman who reports she has had recent multiple sexual partners and says she has used irregular protection against sexually transmitted disease (STD). You order lab tests, including a screen for chlamydia. When positive results return the next day, will she come back for treatment?
-
Do you know how to assess patients for subarachnoid hemorrhage (SAH), the most deadly type of stroke? A new study has dramatic implications for ED care of these patients.
-
An adult patient with fever and cough. This is something you probably see at least once a day and perhaps dozens of times a day in your ED during the flu season. But did you know about new recommendations that call for changes concerning when patients receive antibiotics, which diagnostic tests they are given, and whether they are discharged or admitted?
-
CryoCor (San Diego, California) said it has initiated its first U.S. multi-center pivotal clinical trial under a protocol approved by the FDA to treat atrial flutter with its CryoCor Cardiac Cryoablation System. CryoCors system is the first cryoablation device to be entered into a clinical pivotal trial in the U.S. for the treatment of atrial flutter, one of the leading causes of hospitalization due to rapid heart rhythm, the company said.
